Latest Safety News

Lunnon Metals has won a Western Australian government grant to fund diamond drilling at its promising Plentiful Dolerite gold target, located within the prolific Kambalda gold district. This initiative aims to test a potentially blind gold system analogous to nearby major mining complexes.

Western Yilgarn NL has secured exploration licences for the Cardea 1 and 2 Bauxite Projects in Western Australia, revealing promising high-grade bauxite results from extensive drilling. The projects' proximity to infrastructure and strong assay data position the company well for future resource development.

Prescient Therapeutics has reached a pivotal milestone by dosing the first patient in its Phase 2a clinical trial of PTX-100 for relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), aiming to evaluate safety and efficacy across multiple international sites.

Talius has deepened its partnership with Silverchain Group to pilot an AI voice assistant aimed at transforming home aged care services, starting with appointment scheduling in Western Australia and eyeing a national rollout.

Vulcan Energy has begun drilling the first new well for its Phase One Lionheart Project in Germany, marking a critical step toward expanding its renewable geothermal energy and lithium production capacity.

Yowie Group has posted its first profitable seasonal quarter, driven by strategic cost control and product improvements, but faces ongoing capital challenges due to a significant loan default by Keybridge Capital.

Veris Limited has secured over $2 million in new digital project contracts, reinforcing its leadership in spatial data consulting across energy, transport, and government sectors. These wins highlight the company’s innovative use of proprietary platforms and advanced data capture technologies.

PYC Therapeutics has secured approval to escalate dosing in its Phase 1a trial of PYC-003 for Polycystic Kidney Disease, moving closer to patient dosing later this year.

Elders Limited has reported a robust 67% increase in underlying EBIT for the first half of FY25, driven by higher livestock prices and strategic acquisitions, while navigating challenges from dry weather impacting crop inputs.

Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.

EROAD Limited reported solid financial results for FY25, with revenue up 6.8% to NZ$194.4 million and a substantial improvement in free cash flow to NZ$16 million. The company’s strategic focus on enterprise fleet growth and innovation underpins a confident FY26 guidance.

GreenHy2 Limited has broadened its renewable energy storage portfolio by integrating graphene-based hybrid supercapacitor batteries, reporting robust FY24 growth and advancing key customer trials.